The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
Completed
- Conditions
- Pulmonary ThromboembolismPulmonary Embolism (PE)
- Interventions
- Other: Non-Interventional
- Registration Number
- NCT03595891
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 660
Inclusion Criteria
- Adults participants at date of admission
- Primary presentation consistent with PE followed by objectively-confirmed acute PE
- Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge
Exclusion Criteria
- PE diagnosed during a hospital admission for a reason other than PE during the study period
- Patients receiving anticoagulation at the time of presentation
- Patients presenting outside the defined study period
Other protocol defined inclusion/exclusion criteria could apply
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Adult with acute PE after the introduction of apixaban Non-Interventional - Adult with acute PE before the introduction of apixaban Non-Interventional -
- Primary Outcome Measures
Name Time Method Compare the average length of stay in secondary care 60 days
- Secondary Outcome Measures
Name Time Method Distribution of clinical characteristics of patients admitted with a PE Baseline Clinical characteristics will be summarized using descriptive statistics
Distribution of demographic data of patients admitted with a PE Baseline Demographic data will be summarized using descriptive statistics
Total length of stay, including repeat admissions During the first 30 days after presentation of PE
Trial Locations
- Locations (1)
Local Institution
🇬🇧Cardiff, United Kingdom